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Abstract
The potent vasoconstrictor peptides, endothelin 1 (ET-1) and angiotensin II control adaptation of blood vessels to
fluctuations of blood pressure. Previously we have shown that the circulating level of ET-1 is regulated through its
proteolytic cleavage by secreted serine carboxypeptidase, cathepsin A (CathA). However, genetically-modified mouse
expressing catalytically inactive CathA S190A mutant retained about 10–15% of the carboxypeptidase activity against ET-1
in its tissues suggesting a presence of parallel/redundant catabolic pathway(s). In the current work we provide direct
evidence that the enzyme, which complements CathA action towards ET-1 is a retinoid-inducible lysosomal serine
carboxypeptidase 1 (Scpep1), a CathA homolog with previously unknown biological function. We generated a mouse strain
devoid of both CathA and Scpep1 activities (DD mice) and found that in response to high-salt diet and systemic injections of
ET-1 these animals showed significantly increased blood pressure as compared to wild type mice or those with single
deficiencies of CathA or Scpep1. We also found that the reactivity of mesenteric arteries from DD mice towards ET-1 was
significantly higher than that for all other groups of mice. The DD mice had a reduced degradation rate of ET-1 in the blood
whereas their cultured arterial vascular smooth muscle cells showed increased ET-1-dependent phosphorylation of myosin
light chain 2. Together, our results define the biological role of mammalian serine carboxypeptidase Scpep1 and suggest
that Scpep1 and CathA together participate in the control of ET-1 regulation of vascular tone and hemodynamics.
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Introduction
Vascular resistance of the mammalian circulation system is
tightly regulated by many endogenous agents that influence the
blood volume, and diverse functions of endothelium, vascular
smooth muscle and myocardium. When the balance of these
agents is disturbed, persistent systemic hypertension develops.
Short regulatory peptides, endothelin-1 (ET-1) and angiotensin II
(AII) are recognized among the most potent vasoactive regulators.
Through their interaction with cell surface receptors both peptides
can modulate blood pressure by contracting arteries, or by
induction or suppression of vascular wall remodelling.
ET-1 also has mitogenic effects on vascular endothelium and
smooth muscle [1], stimulates the secretion of atrial natriuretic
peptide ANP and aldosterone and inhibits the release of renin to
counteract its effects [2]. The elevated ET-1 values have been
previously observed in human vascular and cardiovascular
disorders such as acute myocardial infarction, congestive heart
failure, ischemia, atherosclerosis, hypercholestemia, systemic and
pulmonary hypertension [3]. ET-1 deficient mice showed abnor-
mal fetal development and haemodynamics [4], whereas the
overexpression of human ET-1 in mice caused vascular remod-
elling and endothelial dysfunction [5,6].
AII is another potent blood pressure-inducing and mitogenic
peptide that belongs to the renin-angiotensin system. It is derived
from the precursor, angiotensin I (AI) by angiotensin converting
enzymes (ACE or ACE2). Inhibitors of AII receptors, as well as
ACE inhibitors normalize the high blood pressure and decrease
inward remodelling of arteries [7].
The bioavailability and potency of AII and ET-1 can be
regulated through many factors such as alteration of receptor
density and affinity, up- and down-regulation of peptide synthesis
or release, enzymatic activation (ACE and ACE2 for AII, ECE
and MMP-2 for ET-1 [8]), or degradation (neutral endopeptidase
NEP for ET-1 [9–11]). Previously we have shown that circulating
ET-1 is inactivated by lysosomal carboxypeptidase, cathepsin A
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(CathA) widely distributed in mammalian tissues (reviewed in
[12]). The majority of CathA in the cell is found in the lysosome
but significant pool of the enzyme is also present at the cell surface
and secreted outside the cell [12]. In vitro CathA rapidly inactivates
ET-1 by converting it into biologically inactive des-Trp21-
endothelin-1 [13,14]. CathA also hydrolyze the last residue of
AI transferring it into angiotensin 1–9 (A1–9), which can be
further converted into AII by ACE, but at much slower rate [15–
17]. We reported that a gene-targeted mouse expressing
enzymatically inactive CathA with a Ser190Ala mutation in the
active site nucleophile [18] showed reduced degradation rate of
ET-1 and significantly increased arterial blood pressure. At the
same time, tissues of CathAS190A mice retained about 10–15% of
the carboxypeptidase activity measured against ET-1 suggesting
presence of parallel/redundant catabolic pathway(s) [18].
In the current work we tested whether the source of the
complementary ET-1-degrading activity is a lysosomal serine
carboxypeptidase 1 (Scpep1), a CathA homolog with previously
unknown physiological function. Our results show that mice with a
double CathA/Scpep1 deficiency (DD mice) demonstrate hyper-
tension, increased ET-1-induced vasoconstriction and prolonged
half-life of circulating ET-1 as compared to both wild type (WT)
animals and those with single CathA or Scpep1 deficiencies,
strongly supporting this hypothesis.
Results
Scpep1 has carboxypeptidase activity against ET-1
Mice with a combined deficiency of CathA and Scpep1 were
obtained by intercrossing previously described CathAS190A and
Scpep12/2 mouse lines, both in C57BL/6NCrl genetic back-
grounds. Double heterozygous mice were crossed to obtain double
homozygous CathAS190A/Scpep12/2 progeny, and their genotypes
were confirmed by PCR of tail DNA (Fig. S1). CathAS190A/
Scpep12/2 mice (double-deficient mice, DD) were viable and born
in the frequency expected from Mendelian inheritance (16 of 307)
indicating that combined deficiency of both enzymes does not
cause embryonic lethality. CathAS190A/Scpep12/2 mice showed
normal growth, were behaviourally indistinguishable from WT
animals and could be bred to produce knockout litters.
The amount Scpep1 mRNA measured by RT-q-PCR in aorta,
hear and kidney tissues of Scpep12/2 and CathAS190A/Scpep12/2
mice (Fig. S2) was below detection limit. Carboxypeptidase activity
against ET-1 assayed in cultured AVSMC of CathAS190A mice was
reduced to ,10% of activity in WT mice whereas the activity in
tissues of Scpep12/2 mice was reduced to ,70% (Fig. 1A). In the
CathAS190A/Scpep12/2 mice carboxypeptidase activity was ,6% of
WT and significantly lower than that in CathAS190A mice, indicating
that Scpep1 partially contributes to ET-1 hydrolysis (Fig. 1A). The
activity of Scpep1 against ET-1 was further confirmed when the
AVSMC of CathAS190A/Scpep12/2mice were transiently transfected
with Scpep1-expressing plasmid [19]. The level of carboxypeptidase
activity measured with ET-1 in the transfected cells was significantly
higher then in non-transfected cells or cells transfected with control
plasmid, coding for green fluorescent protein (Fig. 1A) and similar to
that in the cells of CathAS190A mice, despite the modest transfection
level of ,5% that could be achieved in the primary AVSMC
cultures. In contrast when we transfected AVSMC from WT mice
with a lentiviral vector expressing shRNA for Scpep1 the
carboxypeptidase activity against ET-1 in the cell homogenate in
the transfected cells was reduced by ,50%, consistent with that in
the AVSMC from Scpep12/2 mice. In the cells transfected with
CathA shRNA-expressing vector the activity was decreased by
,90% and in the cells transfected with scrambled RNA constructs,
not changed (Fig. 1B).
Finally, to test directly if Scpep1 has carboxypeptidase activity
against ET-1 we have expressed the protein, carrying a His6 tag at
the C-terminus (Scpep1-His6) in HT1080 cells [19]. The secreted
protein was purified until electrophoretic homogeneity by affinity
chromatography on Ni-NTA resin followed by anion-exchange
chromatography on Poros HQ resin (Fig. S3) and its carboxy-
peptidase activity was assayed as above with 50 mM ET-1 as a
substrate. We found that at pH 5.5 purified Scpep1-His6 was
capable of cleaving the C-terminal Trp residue from ET-1 at a
rate of 23.6 mmol/h per mg of protein (Fig. 1C), i.e. close to that of
purified CathA [20]. Lower activity was observed at higher pH of
6.5 and 7.5 (Fig. 1C).
Scpep1 deficiency contributes to a further increase of
blood pressure in CathA-deficient mice
The heart rate (HR) and blood pressure (BP) in WT, CathAS190A,
Scpep12/2 and double-mutant CathAS190A/Scpep12/2 male mice
was measured by radiotelemetry over a 3-day period. Then, the
mice were challenged by a high salt diet (8% NaCl for 2 weeks)
with continuous measurement of BP and HR.
The day (Fig. 2A, C) and night (Fig. 2B, D) levels of systolic BP
(SBP) were significantly increased in CathAS190A animals as
compared with WT both before and during a high-salt diet,
whereas the BP levels in Scpep12/2 animals were similar to that of
WT. Night SBP in CathAS190A/Scpep12/2 mice was significantly
different from that of WT, Scpep1-deficient and CathA-deficient
animals (Fig. 2 and Fig. S4). The HR values (Fig. S5) and the
parameters characterizing kidney function (water intake, urine
volume, urine sodium and urine creatinine levels, Fig. S6) were
similar for all strains suggesting that the observed increase in SBP
in DD mice relates to a vascular effect reflecting potential roles of
Scpep1 and CathA in conversion of vasoconstrictive peptides. This
hypothesis was further tested by measuring changes in BP in
response to ET-1 and AI, the precursor of vasoconstrictive peptide
AII. The changes in the diastolic and systolic BP (DDBP and
DSBP, respectively) were calculated as the differences between the
measured BP values and the basal values measured for the 30 min
interval preceding the injection. To reduce the impact of the stress
on BP caused by animal handling/injection, animals were
Author Summary
Arterial blood pressure is regulated by small peptide
hormones (vasoactive peptides) that cause contraction or
relaxation of the arterial wall. The blood and tissue levels
of these peptides are controlled by two mechanisms:
through their synthesis and through their inactivation by
the enzymes that are capable of cleaving them. Our results
demonstrate that vasoactive peptide endothelin-1, is
inactivated by two homologous enzymes, lysosomal serine
carboxypeptidase, cathepsin A and lysosomal serine
carboxypeptidase 1. We have developed a mutant strain
of mice that do not produce both enzymes and found that
these mice rapidly develop high blood pressure and show
a reduced degradation rate of endothelin-1. We also found
that endothelin-1 causes higher contraction of arteries
from mutant than from normal mice or mice that are
deficient only in one of the two enzymes. Our mouse
model provides insight into the functional engagement of
lysosomal serine carboxypeptidases in pathophysiology of
hypertension and may become a tool to explore whether
induction of these enzymes would have any therapeutic
value.
Serine Carboxypeptidases Regulate Vasoconstriction
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receiving daily saline injections for 3 days prior to the experiment.
The data (Fig. 3) indicate that the BP response to the i.v. injections
of ET-1 was significantly (p,0.0001) dependent on animal
genotype. The effect of ET-1 in Scpep-1-deficient mice was not
significantly different from that in WT animals: there was no BP
increase in response to the low (0.2 nmol/kg) dose of ET-1 and
similar increase in response to the high (5 nmol/kg) dose. While
CathA-deficient animals showed a higher response to ET-1 at the
Figure 1. Scpep1 has carboxypeptidase activity against ET-1. A. Carboxypeptidase activity against ET-1 in homogenates of cultured AVSMC
from WT, Scpep12/2, CathAS190A and Scpep12/2/CathAS190A mice as well as from the cells of Scpep12/2/CathAS190A mice transiently transfected with
pCMV-GFP and pCMV-Scpep1 plasmids. AVSMC after the passage 3 were transfected or not with Scpep1-RGS-His-Tag and pEGFP-C1 plasmids. Forty-
eight hours after transfection confluent cells were harvested, homogenized and tested for carboxypeptidase activity using 50 mM ET-1 as a substrate.
Data are expressed as means (6S.D.) of 3 independent experiments performed with different cell cultures. * p,0.05 and ** p,0.01 in two-tailed
unpaired t-test. B. Carboxypeptidase activity against ET-1 in homogenates of cultured AVSMC from WT mice transfected with Scpep1 and CathA
shRNA. AVSMC after the passage 3 were transfected with pRFP-C-RS vectors expressing shRNA for mouse CathA and Scpep1 or non-effective 29-mer
scrambled shRNA as indicated. Seventy-two hours after transfection the cells were harvested, and those expressing plasmids enriched by cell-sorting,
homogenized and tested for carboxypeptidase activity using 50 mM ET-1 as a substrate. Data are expressed as means (6S.D.) of 3 independent
experiments performed with different cell cultures. ** Significantly different from non-transfected or scrambled shRNA-transfected cells; p,0.01 in
two-tailed unpaired t-test. C. Carboxypeptidase activity against ET-1 of purified recombinant Scpep1. Scpep1 carrying a His6 tag at the C-terminus
was expressed in stably transfected HT1080 cells and purified by affinity chromatography on Ni-NTA resin followed by anion-exchange
chromatography as described [19]. Carboxypeptidase activity was assayed with 50 mM ET-1 as a substrate and 0.4–0.8 mg of the purified enzyme in
the reaction mixture in 50 mM sodium phosphate/50 mM sodium acetate buffer at pH 5.5, 6.5 and 7.5. Bars show mean values (6S.D.) of 3
independent experiments. In separate experiments we confirmed that under the conditions used the amount of liberated amino acid was directly
proportional both to the incubation time and to the amount of Scpep1 protein in the reaction mixture (inset graphs). The amino acid analysis of the
reaction mixture determined that Scpep1 cleaves the C-terminal amino acid (Trp21) from ET-1 (not shown).
doi:10.1371/journal.pgen.1004146.g001
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low dose as compared to WT or Scpep1-deficient animals only,
DD animals showed a higher response as compared to all other
groups of mice (Fig. 3A, B). After injection of ET-1 at the high
dose the BP in DD mice remained significantly elevated for at least
60 min, whereas in WT or single knockout mice it decreased
already after 40 min (Fig. 3C, D). The effect of AI on BP was
similar in all animal groups (Fig. S7).
Scpep1 deficiency increases the vasoconstrictive
response of mesenteric arteries to ET-1 but not to AI
The vasoreactivity of mesenteric arteries from the four groups of
male mice was directly measured in ex-vivo tests. Isolated arteries
were exposed to ET-1 and the precursor of AII, AI as well as to
known vasodilators (acetylcholine, ACh and sodium nitroprusside,
SNP) and vasoconstrictors (norepinephrine, NE. We observed no
differences in vessel reactivity in response to ACh, SNP or NE
(Fig. 4A, B, C) as well as to AI (Fig. S8) between the four groups of
mice. Reactivity to ET-1 was higher for CathAS190A and Scpep12/2
than for WT mice (Fig. 4D). The reactivity of vessels from
CathAS190A/Scpep12/2 mice to ET-1 was significantly higher than
that for all other groups of mice consistent with the in vivo data
showing bigger increase of BP in CathAS190A/Scpep12/2 mice in
response to ET-1 (Fig. 4D).
Cultured AVSMC of CathAS190A/Scpep12/2 mice show
increased phosphorylation of myosin light chain
To verify at the molecular level if AVSMC from CathAS190A/
Scpep12/2 mice have increased reactivity to ET-1, we studied
intracellular signalling events in these cells in response to ET-1. ET-
1 interacts with G-protein-associated endothelin type A (ETR-A)
and type B (ETR-B) receptors on the surface of AVSMC. Activation
of the receptors induces phospholipase C and increases the
intracellular Ca2+ level leading to activation of myosin light chain
kinase that phosphorylates myosin light chain (MLC) [21–24]. This
causes contraction of myosin filaments and shrinkage of the cells.
We therefore, compared the level of MLC phosphorylation in
AVSMC before or after treatment with ET-1 for the 4 strains of
mice. AVSMC cultured overnight in serum-free medium were
treated with or without 100 nM ET-1, harvested and analyzed by
Western blot using antibodies against MLC-2 phosphorylated at
Thr18 and Ser19 residues or against total MLC protein. MLC-2
phosphorylation was blocked by pre-treatment of the cells with the
Figure 2. Mice with combined CathA/Scpep1 deficiency show significantly higher values of SBP. Blood pressure was recorded
continuously during day (A and C) and night (B and D) 12-h periods in 16 week-old WT, Scpep12/2, CathAS190A and DD male mice. Arrows indicate
commencement of high salt diet. Two-way repeated measurements ANOVA was used to test differences between the mouse groups: significant
differences between the mean BP values in Bonferroni post-test (* p,0.05, ** p,0.001, *** p,0.0001) are shown in the insert. N-value for each
genotype is as follows: WT n=5, DD n=6, CathAS190A n=6, Scpep12/2 n= 7.
doi:10.1371/journal.pgen.1004146.g002
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known pharmacological antagonist of ETR-A, BQ610, and ETR-B
antagonist, BQ788, suggesting that this effect is dependent on ET-1
action on its receptors (Fig. 5A). The cells from CathAS190A/Scpep12/2
mice had significantly higher level of pThr18/pSer19-MLC-2: ,2
times higher than that in the control, CathA-deficient or Scpep1-
deficient cells, and elevated basal levels of MLC-2 phosphorylation
(Fig. 5B).
CathAS190A/Scpep12/2 mice demonstrate elevated levels
of plasma ET-1
To determine the ET-1 degradation rate we injected mice in the
tail vein with an ET-1 solution in saline at a dose of 0.1 nmol/kg
BW. Fifteen minutes after injection mice were sacrificed and their
lungs and aorta as well as blood were collected to measure the
concentration of ET-1 by ELISA. Endogenous levels of ET-1 were
Figure 3. Mice with combined CathA/Scpep1 deficiency show higher increase in BP in response to systemic injection of ET-1. Sixteen
week-old WT, Scpep12/2, CathAS190A and DD male mice kept for two weeks on high-salt diet were intravenously injected with ET-1 solution in saline
at a dose of 0.2 nmol/kg (A, B) and 5 nmol/kg (C, D). Changes in the systolic (DSBP) or diastolic (DDBP) blood pressure were calculated as differences
between the means (6S.E) of the BP values recorded within 10 min intervals after the injections and means (6S.E) of the baseline BP values recorded
within the 30 min interval before the injections. Two-way repeated measurements ANOVA was used to test differences between the mouse groups:
significant differences between the mean BP values in Bonferroni post-test (* p,0.05, ** p,0.001, *** p,0.0001) are shown in the insert. N-value for
each genotype is as follows: WT n= 5, DD n=6, CathAS190A n=6, Scpep12/2 n= 7.
doi:10.1371/journal.pgen.1004146.g003
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measured in the animals injected with saline. Our data show that,
15 min after the ET-1 injection, its concentration in lungs (Fig. 6A)
and aorta (Fig. 6B) of CathA-deficient mice was higher than that in
the WT or Scpep1-deficient animals thus confirming our previous
findings about the involvement of this enzyme in the ET-1
degradation. In tissues or plasma of DD mice the concentration of
ET-1 was significantly higher than that in WT, CathA-deficient or
Scpep1-deficient mice suggesting that in CathAS190A/Scpep12/2
mice the degradation rate of ET-1 is considerably reduced. No
differences in endogenous circulating levels of ET-1 (Fig. 6D) were
recorded.
Discussion
Scpep1 was originally identified in rat aortic smooth muscle cells
by screening for retinoid inducible genes [25]. Retinoids, natural
and synthetic derivatives of vitamin A, block SMC proliferation
and attenuate neointimal formation after vascular injury, presum-
ably through retinoid receptor-mediated changes in gene expres-
sion. High transcript levels of Scpep1 were detected in kidney,
lungs and heart. Scpep1 was localized to lysosomes by immuno-
fluorescence, subcellular fractionation assays and mannose 6-
phosphate receptor binding [19,26].
Figure 4. ET-1 causes significantly stronger constriction in mesenteric arteries from mice with Scpep1 deficiency. Mesenteric arteries
isolated from sixteen week-old WT, Scpep12/2, CathAS190A and DD male mice were treated with increasing concentrations of Ach (A), SNP (B) NE (C)
and ET-1 (D). ET-1 caused significantly (p,0.01 two-way repeated measurements ANOVA) higher constriction of arteries from DD, CathAS190A and
Scpep12/2 as compared to those from mice with other genotypes. Bonferroni post test: * p,0.05 ** p,0.01, *** p,0.001. N-value of each genotype is
as follows: WT n= 8, DD n=8, CathAS190A n=6, Scpep2/2 n= 6.
doi:10.1371/journal.pgen.1004146.g004
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Scpep1 shows high similarity to other members of the serine
carboxypeptidase family and, in particular, to CathA. Like CathA,
Scpep1 has a cleavable signal peptide, N-linked glycans, the Ser-
Asp-His catalytic triad and is proteolytically processed from a
55 kDa precursor into the 35 kDa and 18 kDa fragments [19].
Scpep1 gene-interrupted mice generated by us using a gene trap
technology are fertile, have normal growth, normal clinical blood
and urine parameters and did not have pathological changes in
any tissue examined [19]. Later study by Lee at al. [27] reported
that the Scpep1-null mice generated by replacing exons 1 and 2 of
the Scpep1 gene with Neo cassette show a decrease in medial and
intimal cell proliferation as well as in vessel remodelling following
arterial injury. The same study also reported that a ,50%
knockdown of endogenous Scpep1 in mouse ASMC line showed
dramatic decrease in serum-stimulated growth. This study did not
identify a physiological substrate of Scpep1, but the authors
concluded that Scpep1 and CathA have distinct functions and
‘‘non-overlapping pools of substrates that function in cardiovas-
cular homeostasis’’.
Our current data, however, provide evidence that both
carboxypeptidases catabolize at least one common substrate,
ET-1. Mice devoid of both CathA and Scpep1 activities show
significantly higher BP on both normal and high-salt diet or in
response to systemic injections of ET-1 as compared to WT mice
or those with single deficiencies of CathA or Scpep1. ET-1 also
causes higher constriction of mesenteric arteries from DD mice.
Since the effects of other tested vasodilators and vasoconstrictors
are similar, these results are consistent with increased sensitivity of
arterial smooth muscle to ET-1. Indeed, in cultured AVSMC from
DD mice ET-1 caused significantly increased phosphorylation of
MLC-2 as compared with the control, CathA-deficient or Scpep1-
deficient cells. Finally, the degradation rate of ET-1 in the blood
plasma or aorta and lung tissues was significantly reduced in DD
as compared to WT, CathA-deficient or Scpep1-deficient mice.
The cardiovascular effects of AI and AII concentration in
mouse plasma (S. Ernest, unpublished) were similar in WT,
CathA-deficient, Scpep1-deficient and DD mice. This contradicts
previously proposed role of CathA in the generation of AII from
AI [15–17] and suggests that in general ET-1 and AII are
controlled by different sets of proteases. We cannot exclude,
however, that CathA still may participate in AII regulation in
specific tissues, such as heart atrium, where the rate of AI
conversion to A1–9 by CathA constitutes ,25% of that to AII by
ACE [17]
Our data indicate that in mouse tissues CathA is sufficient for
inactivation of ET-1, which justifies the apparent absence of
Figure 5. Cultured AVSMC from mice with combined CathA/Scpep1 deficiency show increased reactivity to ET-1. A. Pharmacological
antagonists of ET receptors, BQ610 and BQ788, reduce MLC-2 phosphorylation in AVSMC treated with ET-1. Cultured AVSMC from WT mice were
treated or not for 30 min with 2 mM BQ610 or BQ788 followed by 5 min induction with 100 nM ET-1 as indicated on the figure. Total protein extracts
were analyzed by Western blotting using antibodies specific for phosphorylated (pThr18/Ser19-MLC) and total MLC-2 protein. Panel shows
representative data of 3 independent experiments. Right panels show ratios (means and S.D.) of signal intensities for phosphorylated and total MLC-2
estimated with ImageQuant software. * p,0.05 in paired two-tailed t-test. B. Increased MLC-2 phosphorylation in AVSMC from double-deficient mice.
Cultured AVSMC from WT, Scpep12/2, CathAS190A and DD mice were treated for 5 min with 100 nM ET-1. Total protein extracts were analyzed by
Western blotting using antibodies specific for phosphorylated and total MLC-2 protein. Panel shows representative data of 3 independent
experiments. Graph below the panel shows ratios (mean values and S.D.) of signal intensities for phosphorylated and total MLC-2 protein. * p,0.05 in
paired two-tailed t-test.
doi:10.1371/journal.pgen.1004146.g005
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phenotype in our line of Scpep1 KO mice. In contrast, Scpep1
activity is unable to fully compensate for the loss in CathA activity
in the knock-in CathA-deficient mice that show elevated blood
pressure [18]. In the absence of CathA, the Scpep1 activity
becomes essential for degradation of ET-1 as demonstrated by
induced BP and contractility of arteries in DD as compared to
singe CathA KI mice. Importantly, CathA has also other functions
non-overlapping with those of Scpep1, such as activation of
sialidase Neu1 in the lysosome [12], regulation of elastogenesis
through its function in elastin-binding protein complex [28,29]
and inactivation of bradykinin [30]. Intravenous bolus injections of
potent specific CathA inhibitors induced bradykinin-dependent
diuresis [30], however in our experiments we did not see a
difference in the urine volume between WT and CathA-deficient
mice. One possible explanation is that CathA KI animals could
adapt to deficiency of CathA by reducing bradykinin production
or the number of bradykinin receptors.
The expression of Scpep1 in cardiovascular tissues can be
effectively induced by retinoic acid, potentially providing a
metabolic bypath to correct arterial hypertension attributed to a
deficiency in ET-1 degradation in galactosialidosis patients with
mutations in the CATHA gene [31,32]. Interestingly all-trans
retinoic acid has been shown to inhibit pulmonary hypertension
induced by monocrotaline in rats [33], whereas human patients
with idiopathic pulmonary arterial hypertension were shown to
have reduced retinoic acid levels [34]. The anti-hypertensive effect
of retinoic acid treatment was attributed to its ability to elicit
growth-inhibitory signals in pulmonary artery smooth muscle cells
and influence pulmonary vascular remodelling [34–36], while our
current data allow to propose that it may be also related to the
induction of Scpep1 followed by increased degradation of ET-1.
Together, our results define a biological role of Scpep1 protein,
and suggest that Scpept1 and CathA participate together in the
control of ET-1 regulation of vascular tone and hemodynamics.
Methods
Animals
Generation of mice containing Ser190Ala point mutation in the
CathA active site (CathAS190A strain) and those with the Scpep1 gene
interrupted by gene-trap technology (Scpep12/2 strain) have been
described [18,19]. In the Scpep1 gene-trap mouse b-galactosidase/
neomycin phosphotransferase (geo) fusion gene was inserted into
intron 7 of the Scpep1 gene resulting in deletion of downstream
exons 8–13 encoding in particular the putative catalytic triad
amino acids, Asp371 and His431 from the gene trap transcript.
Figure 6. Mice with combined CathA/Scpep1 deficiency have reduced ET-1 degradation rate. Blood plasma, lungs and aorta were
collected from WT, Scpep12/2, CathAS190A and DD mice 15 min post an intravenous injection of saline or ET-1 in saline (10 nmol/kg BW). The levels of
ET-1 peptide were measured by ELISA in lung extracts (A), aorta extracts (B), and in blood plasma extracts (C) from mice injected with ET-1 and blood
plasma extracts from mice injected with saline (D). Data are expressed as mean values (6S.E). At least 5 mice were studied for each genotype. * p,
0.05 in Welch’s modification of two-tailed unpaired t-test.
doi:10.1371/journal.pgen.1004146.g006
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The amount of Scpep1 mRNA and protein measured by Northern
and Western blots in liver, kidney, heart, brain spleen and lung
tissues of Scpep12/2 mice [19] as well as the amount Scpep1 mRNA
measured by RT-q-PCR in aorta, hear and kidney tissues (Fig. S2)
was reduced below detection threshold of the methods.
Both strains were back-crossed for at least 5 generations to
C57BL/6NCrl strain distributed by Charles River (QC, Canada).
Homozygous animals from each genotype were cross-bread to
obtain the Scpep1-deficient, CathA-deficient, double-mutant and
wild type mice. Mice were housed in an enriched environment
with continuous access to food and water, under constant
temperature and humidity, on a 12 h light:dark cycle. Approval
for the animal care and the use in the experiments was granted by
the Animal Care and Use Committee of the Ste-Justine Hospital
Research Center.
Genotyping of mice
50 ml of PCR mixture contained 100 pmol of each primer,
0.2 mM dNTPs, 1.5 U taq polymerase (Feldan, 9K-001-0002) and
100 ng of genomic DNA from clipped tail tips in 20 mM Tris
(pH 7.4), 50 mM KCl, and 1.5 mM MgCl2. Multiplex primers for
detection of Scpep1 alleles were 59-ATCCTCACACATG-
CAAAGCA (Scpep1-F), 59-TATTGGGCTGGAGTGGAGAC
(Scpep1-R) and 59- CCTGGCCTCCAGACAAGTAG (Scpep1-
trap) and for detection of CathA alleles, 59-GGTGGCGGAGAA-
CAATTATG (CathA-F) and 59-AACAGAAGTGGCACCCT-
GAC (CathA-R). For Scpep1 allele genotyping, samples were
denatured at 94uC for 2 min, followed by 35 cycles at 94uC for
15 s, 52uC for 15 s and 72uC for 1 min, with a final extension
reaction at 72uC for 30 s. For CathA allele genotyping, samples
were denatured at 92uC for 5 min, followed by 30 cycles at 92uC
for 30 s, 56uC for 30 s and 72uC for 30 s, with a final extension
reaction at 72uC for 5 min. Then the amplification product was
digested with NdeI (Biolabs, R0111S) at 37uC overnight.
Quantitative RT-PCR
Total RNA was isolated from mouse tissues using the Trizol
Reagent (Invitrogen 15596-026) according to the manufacturer’s
protocol and reverse-transcribed using random primers and
QuantiTect Reverse Transcription Kit (QIAGEN 205311).
Quantification of mouse Scpep1 mRNA was performed using an
SsoFast EvaGreen Supermix with Low ROX (BIO-RAD 172-
5210) and the following set of primers: 59- AGCAAGGGAC-
CATTAAGTGC-39 and 59-GCTGAGTGGCCTCCTTGTAG-
39. PCR conditions were as follows: 30 sec at 95uC, followed by 40
cycles of 5 sec at 95uC, 20 sec at 60uC, and 20 sec at 72uC.
RPL32 mRNA was used as a reference control; the data were
expressed as signal ratios between the test gene mRNA and
RPL32 mRNA.
Blood pressure measurements by radiotelemetry
Male CathAS190A mice and appropriate littermate controls were
implanted with TA11PA-C10 radiotelemetry sensors (Data
Sciences International) in the left carotid artery for direct
measurement of arterial pressure and heart rate as described
[37,38]. The transmitter was placed subcutaneously along the left
flank. For basal measurements of mean day and night BP data
were recorded continuously (sampling every hour for 20 sec)
within 16 consecutive days and averaged for 12 h light and dark
intervals. To measure changes in BP after ET-1 and AI injections
data were recorded every 3 min for 2 h and averaged for 10-min
consecutive intervals. At least 7 mice were studied for each
genotype with the exception of WT mice for which only 5 mice
were tested due to sudden death of 2 animals.
Vessel reactivity study
Vessel reactivity ex vivo was analyzed as described [39,40].
Briefly, male mice were sacrificed at five months and their
mesenteric arteries were isolated and mounted onto glass
capillaries in an artereograph chamber filled with cold oxygenated
Krebs solution (118.6 mM NaCl, 4.7 mM KCl, 1.2 mM
KH2PO4, 1.2 mM MgSO4, 25.1 mM NaHCO3, 26 mM EDTA,
0.18% glucose, 2.5 mM CaCl2). The arteries were constantly
perfused intraluminally with Krebs solution at 30 mmHg. After
45 minutes of equilibration vascular reactivity was measured in
response to Norepinephrine (Sigma A-0937, 1029–1025 M),
Acetylcholine (Sigma A-6625, 1029–1024 M), Sodium Nitroprus-
side (Calbiochem 56538, 1029–1024 M), Endothelin-1 (American
Peptide Company 88-1-10, 10211–1028 M) and AI, (American
Peptide Company 12-1-10, 1028–1024 M). Drugs were added
extraluminally with a 30 min washout period in between each
drug, during which the arteries were able to re-equilibrate to a
baseline. To test vasodilatation arteries were pre-contracted with
NE to 70% of their equilibration diameter. At least 3 concentra-
tion response curves were conducted for each vessel and at least 6
animals were studied for each genotype.
Isolation and culture of aortic vascular smooth muscle
cells (AVSMC)
Combined tissues from 5–6 mouse aortas were minced in a
DMEM containing collagenase type I (GIBCO, 17100-017,
3 mg/ml), trypsin (Sigma T-1426, 0.5 mg/ml), and DNAse type
I (Sigma D-4263, 20 mg/ml), incubated at 37uC for 2 h, and
centrifuged for 5 min at 1000 g and 4uC. The cells were
resuspended in 10 ml of DMEM containing 10%FBS, 1%
Antibiotic-Antimycotic (GIBCO 15240-062), 0.5% Fungizone
(GIBCO 15290-018) and maintained in 5% CO2 incubator at
37uC. The medium was changed every three days. After 3
passages 100% of cells were positive to VSMC marker, smooth
muscle a-actin as assayed by FACS with A 2547 antibody (Sigma).
Purification of recombinant mouse Scpep1-His6 from
HT1080 cells
HT1080 cells stably expressing Scpep1-His6 [19] were cultured
in DMEM with 0.05% FCS. Medium was collected three times
every 48 h and subjected to ammonium sulfate precipitation. After
dialysis against PBS, the Scpep1-His6 was purified by metal
affinity chromatography on Ni-NTA agarose (Qiagen) as recom-
mended by manufacturer. The eluate was dialyzed against PBS
and subjected to HPLC anion exchange chromatography
(BiocadVision, Applied Biosystems) by applying a step-wise
gradient up to 500 mM NaCl in PBS. Purity of Scpep1-His6
was monitored by silver staining and Western blotting.
Carboxypeptidase activity assays
Carboxypeptidase activity in cultured AVSMC was measured
against 50 mM ET-1 as previously described using the method
measuring the liberation rate of the C-terminal amino acid of the
peptide [18]. Subconfluent AVSMC were transiently transfected
or not with Scpep1-RGS-His-Tag [19] and pEGFP-C1 (Clontech,
Palo Alto, CA) plasmids, mouse CTSA shRNA (TF501716B/C)
Scpep1 shRNA (TF505007A/B) or non-effective 29-mer scram-
bled shRNA (TR30015) cassette in pRFP-C-RS vector (Origene
Technologies) using Effectene transfection reagent (Qiagen) at a
ratio of 25 ml of Effectene to 1 mg of DNA. Forty eight hours after
transfection (72 h for shRNA constructs) confluent cells were
harvested, homogenized in water by sonication and 50 ml of cell
homogenate was mixed with 100 ml of 0.1 mM ET-1 solution and
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50 ml of 100 mM sodium acetate buffer, pH 5.4, and incubated
for 30–180 min at 37uC. After addition of trichloroacetic acid
(Sigma T0699, 3% final concentration) proteins were removed by
5 min centrifugation at 12,000 g. The 190 ml aliquot of superna-
tant was mixed with 3 ml of 50 mM sodium borate buffer, pH 9.5,
containing 0.15 mg/ml of phthalic aldehyde and 1 mM of beta-
mercaptoethanol (Sigma, M-6250) and incubated at room
temperature for 30 min. The fluorescence was measured at
340 nm excitation and 495 emission wavelength and concentra-
tion of released amino acids determined using a calibration curve
established with 1–100 mM leucine. Carboxypeptidase activity of
recombinant Scpep1-His6 was measured by the same method
using 0.4–0.8 mg of the purified enzyme.
Analysis of myosin light chain 2 phosphorylation by
western blot
AVSMC cultured in 100 mm dishes to confluent layer were
incubated overnight in a serum-free DMEM, and treated for
5 min with 100 nM ET-1. To test the pharmacological inhibition
of the ET-1 receptors the cells were pre-treated for 30 min with
2 mM BQ610 (EMD 203715) or BQ788 (EMD 5223838) before
stimulation with ET-1. The cells were washed with ice-cold PBS,
and lysed in RIPA (RadioImmunoPrecipitation Assay) buffer
containing 50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% NP-40,
0.25% sodium deoxycholate, 0.1% SDS, 2 mM EDTA, 1 mM
PMSF, protease and phosphatase inhibitor cocktails (Roche
04693132001 and 04906837001). Cell lysates were analyzed by
Western blot using anti-phospho-Thr18/Ser19 myosin light chain 2
antibody (Cell Signalling 3674, dilution 1:1000) or anti-myosin
light chain 2 antibodies (Cell Signalling 3672, dilution 1:1000).
Detection was performed with anti-rabbit IgG antibodies-HRP
conjugate (Cell Signalling 7074S), and the enhanced chemilumi-
nescence reagent (Thermo 32106).
Measurement of ET-1 degradation rate in mouse blood
and tissues
Three to four month old mice with 25–35 g body weight (BW)
were anesthetised with urethane (1.5 g/kg BW) and injected into
the tail vein with a solution of ET-1 in saline at a dose of 10 nmol/
kg BW. Fifteen minutes post-injection, blood was collected in
EDTA-coated tubes through cardiac puncture and immediately
centrifuged to separate plasma. Aortas and lungs were dissected
and rapidly frozen in liquid nitrogen.
For peptide extraction, tissues (200 mg) were homogenized in
1 mol/L CH3COOH/20 mM HCl. Plasma was supplemented
with concentrated CH3COOH until the final concentration of
1 mol/L. Samples were boiled for 10 minutes and centrifuged at
20,000 g for 10 minutes. Supernatant was applied to a Strata C18-
E column (Phenomenex, RK-Sepcol-1), washed with 3 volumes of
0.1% TFA in water, and peptides were eluted with 60%
acetonitrile/0.1% TFA, lyophilized, and reconstituted in 0.1%
TFA in DMSO. Quantitative assay of ET-1 was performed with
an ELISA kit (Enzo Life Sciences ADI-900-020A) as described by
the manufacturer.
Statistical analysis
Statistical analysis has been performed using two-tailed paired t-
test (Fig. 1, and 4), Welch’s modification of two-tailed unpaired t-
test (Fig. 5, S2 and S8) and two-way repeated measures ANOVA
(Fig. 2, 3, and 4) tests using Prism Graphpad software. P-value of
0.05 or less was considered significant. Bonferroni post-hoc test
was used to compare specific means, if significance was
determined.
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Supporting Information
Figure S1 Genotyping of WT, Scpep12/2, CathAS190A and double
deficient (DD) mice by PCR analysis of tail genomic DNA. (A)
Scpep1 allele-specific PCR amplifying a 200 bp fragment in wild
type (WT) mice and 390 bp fragment in homozygous Scpep1-
deficient animals (Scpep12/2). (B) CathA allele-specific PCR
followed by NdeI digestion produces a 350 bp fragment in wild
type (WT) mice, and a 250 and 100 bp fragments in homozygous
CathA-deficient animals (CathAS190A).
(PDF)
Figure S2 Scpep1 mRNA expression in mouse tissues. (A)
Schematic representation of WT and Scpep12/2 mRNA showing
the positions of primers for qPCR in Exon 6 and Exon 8. (B) Scpep1
relative mRNA expression in heart, kidney and aorta tissues. Total
RNA was extracted from tissues of 16 week-old WT, Scpep12/2,
CathAS190A and double-deficient (DD) mice and analyzed for Scpep1
expression in different tissues by qPCR. The values were corrected
for the level of control RPL32 mRNA.
(PDF)
Figure S3 Purification of recombinant mouse Scpep1-His6 from
stably expressing HT1080 cells. Scpep1-His6 expressing HT1080
cells (Kollmann et al. 2009, FEBS Journal) were cultured in 0.05%
FCS in DMEM. Medium was collected three times every 48 h and
subjected to ammonium sulfate precipitation. After dialysis to PBS,
the Scpep1-His6 was purified by Ni-NTA agarose (Qiagen). The
eluate was dialyzed to PBS and subjected to HPLC anion exchange
chromatography (BiocadVision, Applied Biosystems) by applying a
step-wise gradient up to 500 mM NaCl in PBS. Purification was
monitored by silver staining and Western blotting. Fractions 9 and
10 were pooled and used for the assay of carboxypeptidase activity.
(PDF)
Figure S4 Mice with combined CathA/Scpep1 deficiency show
significantly higher values of SBP. Diastolic (A) and systolic (B)
blood pressure was recorded continuously (1 measurement per
hour) during day and night 12-h periods in 16 week-old WT,
Scpep12/2, CathAS190A and DD male mice. Arrows indicate
commencement of high salt diet. Two-way repeated measure-
ments ANOVA was used to test differences between the mouse
groups: significant differences between the mean BP values in
Bonferroni post-test (* p,0.05, ** p,0.001, *** p,0.0001) are
shown in the insert. N-value for each genotype is as follows: WT
n=5, DD n=6, CathAS190A n= 6, Scpep12/2 n= 7.
(PDF)
Figure S5 No significant differences were observed between
heart rate in WT, Scpep12/2, CathAS190A and double-deficient (DD)
mice. Heart rate was recorded continuously (once each hour)
during night (A) and day (B) 12-h periods in 16 week-old WT,
Scpep12/2, CathAS190A and double-deficient (DD) mice fed for
three days with normal diet, followed by two weeks on high salt
diet. Arrows indicate commencement of high salt diet. Two-way
ANOVA was used to test differences between the mouse groups.
N-value for each genotype is as follows: WT n=5, DD n=6,
CathAS190A n= 6, Scpep12/2 n= 7.
(PDF)
Figure S6 No significant differences in kidney function were
observed between WT, Scpep12/2, CathAS190A and double-deficient
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(DD) mice. Twenty four hour water intake was measured and urine
collections obtained from 16 week-old male WT, Scpep12/2,
CathAS190A and double-deficient (DD) mice fed with normal diet,
or following two weeks on a high salt diet. Graphs present 24 h
water intake (A) urine sodium (B), urine volume (C) and urine
creatinine (D) measured as previously described. Values are shown
as means (6S.E). N-value for each genotype is as follows: WT n=5,
DD n=6, CathAS190A n=6, Scpep12/2 n=7.
(PDF)
Figure S7 No significant difference was observed in diastolic (A,
B) and systolic (C, D) blood pressure in response to systemic
injections of AI. Sixteen week-old WT, Scpep12/2, CathAS190A and
double-deficient (DD) mice kept for two weeks on a high salt diet
were intravenously injected with AI solution in saline (0.08 and
0.8 nmol/kg BW) or saline only. The pressure was recorded
continuously every 2 min for 30 min before and one hour after
injections. Changes in the blood pressure (DSP or DDP) were
calculated as differences between the BP values recorded within
10 min intervals after the injections and the baseline BP values
recorded within the 30 min interval before the injections. Two-
way repeated measurements ANOVA was used to test differences
between the mouse groups. N-value of each genotype is as follows:
WT n=5, DD n=6, CathAS190A n= 6, Scpep12/2 n= 7.
(PDF)
Figure S8 No significant difference was observed in the AI
induced constriction of mesenteric arteries between CathAS190A,
double deficient (DD) and WT mice. Mesenteric arteries isolated
from sixteen week-old male WT, Scpep12/2, CathAS190A and
double deficient mice were mounted onto glass capillaries in an
artereograph chamber filled with cold oxygenated Krebs solution
and treated with increasing concentrations of AI. Two-way
repeated measurements ANOVA was used to test differences
between the mouse groups. N-value of each genotype is as follows:
WT n=8, DD n=8, CathAS190A n= 6, Scpep12/2 n= 6.
(PDF)
Acknowledgments
We thank Dr. Virginie Dormoy-Raclet for the help with real-time q-PCR
experiments, Mrs. Ines Boufaied for the help with cell-sorting experiments,
Dr. Mila Ashmarina for helpful advice and Mrs. Carmen Movila for the
help in preparation of the manuscript.
Author Contributions
Conceived and designed the experiments: JT JLL AH TL AVP. Performed
the experiments: XP LG VS JP KK. Analyzed the data: XP LG JP JLL TL
AH AVP. Contributed reagents/materials/analysis tools: TL JT JLL AVP.
Wrote the paper: XP LG AVP.
References
1. Yanagisawa M, Masaki T (1989) Molecular biology and biochemistry of the
endothelins. Trends Pharmacol Sci 10: 374–378.
2. Morishita R, Higaki J, Ogihara T (1989) Endothelin stimulates aldosterone
biosynthesis by dispersed rabbit adreno-capsular cells. Biochem Biophys Res
Commun 160: 628–632.
3. Goraca A (2002) New views on the role of endothelin (minireview). Endocr
Regul 36: 161–167.
4. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, et al. (1994)
Elevated blood pressure and craniofacial abnormalities in mice deficient in
endothelin-1. Nature 368: 703–710.
5. Hocher B, Schwarz A, Fagan KA, Thone-Reineke C, El-Hag K, et al. (2000)
Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice.
Am J Respir Cell Mol Biol 23: 19–26.
6. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, et al. (2004) Endothelium-
restricted overexpression of human endothelin-1 causes vascular remodeling and
endothelial dysfunction. Circulation 110: 2233–2240.
7. Morrell NW, Upton PD, Higham MA, Yacoub MH, Polak JM, et al. (1998)
Angiotensin II stimulates proliferation of human pulmonary artery smooth
muscle cells via the AT1 receptor. Chest 114: 90S–91S.
8. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, et al. (1994) ECE-1: a
membrane-bound metalloprotease that catalyzes the proteolytic activation of big
endothelin-1. Cell 78: 473–485.
9. Turner AJ, Murphy LJ (1996) Molecular pharmacology of endothelin converting
enzymes. Biochem Pharmacol 51: 91–102.
10. Thompson JS, Morice AH (1996) Neutral endopeptidase inhibitors and the
pulmonary circulation. Gen Pharmacol 27: 581–585.
11. Winter RJ, Zhao L, Krausz T, Hughes JM (1991) Neutral endopeptidase 24.11
inhibition reduces pulmonary vascular remodeling in rats exposed to chronic
hypoxia. Am Rev Respir Dis 144: 1342–1346.
12. Pshezhetsky AV (2004) Lysosomal carboxypeptidase. In: Barrett AJ, Rawlings
ND, Woessner JF, editors. Handbook of Proteolytic Enzymes. 2nd. ed. London,
UK. pp. 1923–1929.
13. Hanna WL, Turbov JM, Jackman HL, Tan F, Froelich CJ (1994) Dominant
chymotrypsin-like esterase activity in human lymphocyte granules is mediated by
the serine carboxypeptidase called cathepsin A-like protective protein. J Immunol
153: 4663–4672.
14. Itoh K, Kase R, Shimmoto M, Satake A, Sakuraba H, et al. (1995) Protective
protein as an endogenous endothelin degradation enzyme in human tissues.
J Biol Chem 270: 515–518.
15. Miller JJ, Changaris DG, Levy RS (1988) Conversion of angiotensin I to
angiotensin II by cathepsin A isoenzymes of porcine kidney. Biochem Biophys
Res Commun 154: 1122–1129.
16. Kokkonen JO, Saarinen J, Kovanen PT (1997) Regulation of local angiotensin II
formation in the human heart in the presence of interstitial fluid. Inhibition of
chymase by protease inhibitors of interstitial fluid and of angiotensin-converting
enzyme by Ang-(1–9) formed by heart carboxypeptidase A-like activity.
Circulation 95: 1455–1463.
17. Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, et al. (2002)
Angiotensin 1–9 and 1–7 release in human heart: role of cathepsin A.
Hypertension 39: 976–981.
18. Seyrantepe V, Hinek A, Peng J, Fedjaev M, Ernest S, et al. (2008) Enzymatic
activity of lysosomal carboxypeptidase (cathepsin) A is required for proper
elastic fiber formation and inactivation of endothelin-1. Circulation 117: 1973–
1981.
19. Kollmann K, Damme M, Deuschl F, Kahle J, D’Hooge R, et al. (2009)
Molecular characterization and gene disruption of mouse lysosomal putative
serine carboxypeptidase 1. FEBS J 276: 1356–1369.
20. Deng AY, Martin LL, Balwierczak JL, Jeng AY (1994) Purification and
characterization of an endothelin degradation enzyme from rat kidney.
J Biochem 115: 120–125.
21. Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, et al. (2009) ROCK
isoform regulation of myosin phosphatase and contractility in vascular smooth
muscle cells. Circ Res 104: 531–540.
22. Lima VV, Giachini FR, Carneiro FS, Carvalho MH, Fortes ZB, et al. (2011) O-
GlcNAcylation contributes to the vascular effects of ET-1 via activation of the
RhoA/Rho-kinase pathway. Cardiovasc Res 89: 614–622.
23. Wynne BM, Chiao CW, Webb RC (2009) Vascular Smooth Muscle Cell
Signaling Mechanisms for Contraction to Angiotensin II and Endothelin-1. J Am
Soc Hypertens 3: 84–95.
24. Budzyn K, Marley PD, Sobey CG (2006) Targeting Rho and Rho-kinase in the
treatment of cardiovascular disease. Trends Pharmacol Sci 27: 97–104.
25. Chen J, Streb JW, Maltby KM, Kitchen CM, Miano JM (2001) Cloning of a
novel retinoid-inducible serine carboxypeptidase from vascular smooth muscle
cells. J Biol Chem 276: 34175–34181.
26. Kollmann K, Mutenda KE, Balleininger M, Eckermann E, von Figura K, et al.
(2005) Identification of novel lysosomal matrix proteins by proteome analysis.
Proteomics 5: 3966–3978.
27. Lee TH, Chen J, Miano JM (2009) Functional characterization of a putative
serine carboxypeptidase in vascular smooth muscle cells. Circ Res 105: 271–
278.
28. Hinek A, Rabinovitch M, Keeley F, Okamura-Oho Y, Callahan J (1993) The
67-kD elastin/laminin-binding protein is related to an enzymatically inactive,
alternatively spliced form of beta-galactosidase. J Clin Invest 91: 1198–1205.
29. Privitera S, Prody CA, Callahan JW, Hinek A (1998) The 67-kDa enzymatically
inactive alternatively spliced variant of beta-galactosidase is identical to the
elastin/laminin-binding protein. J Biol Chem 273: 6319–6326.
30. Ruf S, Buning C, Schreuder H, Horstick G, Linz W, et al. (2012) Novel beta-
amino acid derivatives as inhibitors of cathepsin A. J Med Chem 55: 7636–7649.
31. Nordborg C, Kyllerman M, Conradi N, Mansson JE (1997) Early-infantile
galactosialidosis with multiple brain infarctions: morphological, neuropatholog-
ical and neurochemical findings. Acta Neuropathol 93: 24–33.
32. Kyllerman M, Mansson JE, Westphal O, Conradi N, Nellstrom H (1993)
Infantile galactosialidosis presenting with congenital adrenal hyperplasia and
renal hypertension. Pediatr Neurol 9: 318–322.
Serine Carboxypeptidases Regulate Vasoconstriction
PLOS Genetics | www.plosgenetics.org 11 February 2014 | Volume 10 | Issue 2 | e1004146
33. Qin Y, Zhou A, Ben X, Shen J, Liang Y, et al. (2001) All-trans retinoic acid in
pulmonary vascular structural remodeling in rats with pulmonary hypertension
induced by monocrotaline. Chin Med J (Engl) 114: 462–465.
34. Preston IR, Tang G, Tilan JU, Hill NS, Suzuki YJ (2005) Retinoids and
pulmonary hypertension. Circulation 111: 782–790.
35. Zhang E, Jiang B, Yokochi A, Maruyama J, Mitani Y, et al. (2010) Effect of all-
trans-retinoic acid on the development of chronic hypoxia-induced pulmonary
hypertension. Circ J 74: 1696–1703.
36. Londhe VA, Maisonet TM, Lopez B, Shin BC, Huynh JC, et al. (2012) Retinoic
Acid Rescues Alveolar Hypoplasia in the Calorie-Restricted Developing Rat
Lung. Am J Respir Cell Mol Biol 48(2):179–87.
37. Lavoie JL, Lake-Bruse KD, Sigmund CD (2004) Increased blood pressure in
transgenic mice expressing both human renin and angiotensinogen in the renal
proximal tubule. Am J Physiol Renal Physiol 286: F965–971.
38. Guo DF, Chenier I, Lavoie JL, Chan JS, Hamet P, et al. (2006) Development of
hypertension and kidney hypertrophy in transgenic mice overexpressing ARAP1
gene in the kidney. Hypertension 48: 453–459.
39. Falcao S, Solomon C, Monat C, Berube J, Gutkowska J, et al. (2009) Impact of
diet and stress on the development of preeclampsia-like symptoms in p57kip2
mice. Am J Physiol Heart Circ Physiol 296: H119–126.
40. Falcao S, Bisotto S, Michel C, Lacasse AA, Vaillancourt C, et al. (2010) Exercise
training can attenuate preeclampsia-like features in an animal model.
J Hypertens 28: 2446–2453.
Serine Carboxypeptidases Regulate Vasoconstriction
PLOS Genetics | www.plosgenetics.org 12 February 2014 | Volume 10 | Issue 2 | e1004146
